Ixabepilone (BMS-247550) | Microtubule Inhibitor

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	219989-84-1
Formula :	C₂₇H₄₂N₂O₅S
M.W :	506.70
SMILES Code :	O=C(C[C@H](O)C1(C)C)N[C@H](/C(C)=C/C2=CSC(C)=N2)C[C@]3([H])O[C@]3(C)CCC[C@H](C)[C@H](O)[C@@H](C)C1=O
Synonyms :	BMS-247550; Aza-epothilone B
MDL No. :	MFCD04307791
InChI Key :	FABUFPQFXZVHFB-PVYNADRNSA-N
Pubchem ID :	6445540

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H317-H334
Precautionary Statements:	P261-P272-P280-P285-P302+P352-P304+P341-P333+P313-P342+P311-P363-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

Docetaxel-resistant MDA-MB-231 cells (TXT)	290 nM	48 hours	Evaluate the effect of Ixabepilone on resistant cell viability, results showed Ixabepilone reduced cell viability to 34.2 ± 3.5% of control.	PMC9584993
MDA-MB-231 parental cells (231C)	22 nM	48 hours	Evaluate the effect of Ixabepilone on cell viability, results showed Ixabepilone significantly reduced cell viability to 29.2 ± 2.0% of control.	PMC9584993
SUM159	5 nM	72 hours	To evaluate the effect of Ixabepilone on cell viability. Results showed that Ixabepilone significantly reduced cell viability in a dose-dependent manner in SUM159 cells (IC50 = 8 ± 2 nM).	PMC4711100
MDA-MB-231	5 nM	72 hours	To evaluate the effect of Ixabepilone on cell viability. Results showed that Ixabepilone significantly reduced cell viability in a dose-dependent manner in MDA-MB-231 cells (IC50 = 10 ± 3 nM).	PMC4711100
HOVTAX2 cells	10 nM	72 hours	Evaluate the antitumor synergy of ixabepilone combined with sunitinib, results showed significant increase in apoptosis	PMC3468155
Human lung cancer cell lines	2.3-19 nM (IC50)	72 hours	Evaluate the cytotoxicity of Ixabepilone against various lung cancer cell lines, showing significant antitumor activity in most cell lines.	PMC3126033
Human colon cancer cell lines	4.7-42 nM (IC50)	72 hours	Evaluate the cytotoxicity of Ixabepilone against various colon cancer cell lines, showing significant antitumor activity in most cell lines.	PMC3126033
Human breast cancer cell lines	1.4-45 nM (IC50)	72 hours	Evaluate the cytotoxicity of Ixabepilone against various breast cancer cell lines, showing significant antitumor activity in most cell lines.	PMC3126033

{[proInfo.proName]}

CAS No.: 219989-84-1

{[proInfo.proName]}

CAS No.: 219989-84-1

Alternative Products

Product Details of Ixabepilone

Safety of Ixabepilone

Related Pathways of Ixabepilone

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

SCID/Beige mice	MDA-MB-231 and SUM159 xenograft models	Intraperitoneal injection	10 mg/kg	Weekly	To evaluate the effect of Ixabepilone on xenograft tumor growth. Results showed that Ixabepilone monotherapy significantly prolonged tumor doubling time (TDT = 25 ± 8 days) in SUM159 xenografts, but the effect was not significant in MDA-MB-231 xenografts.	PMC4711100
Nu/nu mice or Beige SCID mice	Human xenograft models (including NSCLC, breast cancer, and colon cancer)	Intravenous	6-13 mg/kg (intravenous)	Every 4 days for three doses	Evaluate the antitumor activity of Ixabepilone alone or in combination with other anticancer agents, showing significant antitumor effects in various xenograft models, including tumor growth delay and partial or complete regression.	PMC3126033

NCT00751868	Breast Cancer	PHASE2	COMPLETED	2025-07-11	Azienza Osped.Treviglio - Cara... More >>vaggio, Treviglio, BG, 24047, Italy\|Azienda Ospedaliera G. Rummo, Benevento, BN, 82100, Italy\|Ospedale Civile di Campobasso - A. Cardarelli, Campabasso, CB, 86100, Italy\|Ospedale civile Renzetti di Lanciano, Lanciano, CH, 66034, Italy\|Azienda Ospedaliera S. Anna, Como, CO, 22100, Italy\|Azienda Ospedaliera Nesina Garibaldi, Catania, CT, 95124, Italy\|I.S.T. - Istituto Nazionale per la Ricerca sul Cancro, Genova, GE, 16131, Italy\|Presidio Ospedaliero di Macerata, Mecerata, MC, 62100, Italy\|I.R.C.C.S. Multimedica - Casa di Cura Accreditata, Sesto San Giovanni, Milano, 20099, Italy\|Azienda Ospedaliera R. Silvestrini, Perugia, PG, 06132, Italy\|Azienda Ospedaliera SS. Annunziata, Sassari, SS, 07100, Italy\|Ospedale S. Cuore Don Calabria, Negrar, Verona, 37024, Italy\|Ist. Nazionale per lo Studio e la Cura dei Tumori - Fondazione Pascale, Napoli, 80131, Italy\|Università Federico II, Napoli, 80131, Italy\|Istituto Regina Elena, Roma, 00100, Italy Less <<
NCT00005807	Breast Cancer\|Ovarian Cancer\|U... More >>nspecified Adult Solid Tumor, Protocol Specific Less <<	PHASE1	COMPLETED	2025-08-04	Albert Einstein Clinical Cance... More >>r Center, Bronx, New York, 10461, United States\|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, 10016, United States Less <<
NCT00983801	Stomach Neoplasms	PHASE2	COMPLETED	2025-06-11	Local Institution, Hong Kong, ... More >>B, Hong Kong\|Local Institution, Nagoya, Aichi, 4648681, Japan\|Local Institution, Sunto-Gun, Shizuoka, 4118777, Japan\|Local Institution, Seoul, 135-710, Korea, Republic of\|Local Institution, Seoul, 136-705, Korea, Republic of\|Local Institution, Seoul, 138-736, Korea, Republic of\|Local Institution, Singapore, 169610, Singapore\|Local Institution, Taipei, 112, Taiwan\|Local Institution, Taoyuan Hsien, 333, Taiwan Less <<
NCT01019577	Metastatic Breast Cancer	PHASE2	COMPLETED	2025-07-07	-
NCT01018966	Solid Tumors	PHASE1	COMPLETED	2025-04-05	-
NCT00080262	Breast Cancer\|Metastases	PHASE2	COMPLETED	2025-12-06	Local Institution, La Verne, C... More >>alifornia, United States\|Local Institution, Meriden, Connecticut, United States\|Local Institution, Jacksonville, Florida, United States\|Local Institution, Baltimore, Maryland, United States\|Local Institution, Boston, Massachusetts, United States\|Local Institution, New York, New York, United States\|Local Institution, Asheville, North Carolina, United States\|Local Institution, Charlotte, North Carolina, United States\|Local Institution, Pittsburgh, Pennsylvania, United States\|Local Institution, Providence, Rhode Island, United States\|Local Institution, Chattanooga, Tennessee, United States\|Local Institution, Jackson, Tennessee, United States\|Local Institution, Knoxville, Tennessee, United States\|Local Institution, Nashville, Tennessee, United States\|Local Institution, Houston, Texas, United States\|Local Institution, San Antonio, Texas, United States\|Local Institution, Salt Lake City, Utah, United States\|Local Institution, Buenos Aires, Argentina\|Local Institution, Santa Fe, Argentina\|Local Institution, Montreal, Quebec, Canada\|Local Institution, Besancon Cedex, France\|Local Institution, Bobigny, France\|Local Institution, Clermont-Ferrand, France\|Local Institution, Dijon Cedex, France\|Local Institution, Lyon, France\|Local Institution, Marseille Cedex 9, France\|Local Institution, Vandoeuvre Les Nancy, France\|Local Institution, Frankfurt Hoechst, Germany\|Local Institution, Frankfurt, Germany\|Local Institution, Merida, Yucatan, Mexico\|Local Institution, Chihuahua, Mexico\|Local Institution, Distrito Federal, Mexico\|Local Institution, Amsterdam, Netherlands\|Local Institution, Leiden, Netherlands\|Local Institution, Oslo, Norway\|Local Institution, Trondheim, Norway\|Local Institution, Port Elizabeth, Eastern Cape, South Africa\|Local Institution, Fichardtpark, Free State, South Africa\|Local Institution, Pretoria, Gauteng, South Africa\|Local Institution, Overport, Kwa Zulu Natal, South Africa\|Local Institution, Panorama, Western Cape, South Africa\|Local Institution, Helsingborg, Sweden\|Local Institution, Lund, Sweden\|Local Institution, Malmo, Sweden\|Local Institution, Stockholm, Sweden Less <<
NCT00049400	Lymphoma\|Small Intestine Cance... More >>r\|Unspecified Adult Solid Tumor, Protocol Specific Less <<	PHASE1	COMPLETED	2025-12-07	City of Hope Comprehensive Can... More >>cer Center, Duarte, California, 91010-3000, United States\|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, 90089-9181, United States\|University of California Davis Cancer Center, Sacramento, California, 95817, United States\|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, 60153, United States\|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, 66160-7357, United States\|Case Comprehensive Cancer Center, Cleveland, Ohio, 44106, United States\|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States\|Community Oncology Group at Cleveland Clinic Cancer Center, Independence, Ohio, 44131, United States\|Cleveland Clinic - Wooster, Wooster, Ohio, 44691, United States\|Brooke Army Medical Center, Fort Sam Houston, Texas, 78234, United States\|Wilford Hall Medical Center, Lackland AFB, Texas, 78236, United States\|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229-3900, United States\|St. Joseph Hospital Community Cancer Center, Bellingham, Washington, 98225, United States\|Olympic Hematology and Oncology, Bremerton, Washington, 98310, United States\|Skagit Valley Hospital Cancer Care Center, Mt. Vernon, Washington, 98273, United States\|Group Health Central Hospital, Seattle, Washington, 98104-1387, United States\|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98104, United States\|Harborview Medical Center, Seattle, Washington, 98104, United States\|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, 98122-4307, United States\|University Cancer Center at University of Washington Medical Center, Seattle, Washington, 98195-6043, United States\|North Puget Oncology at United General Hospital, Sedro-Wooley, Washington, 98284, United States\|Cancer Care Northwest - Spokane South, Spokane, Washington, 99202, United States\|Wenatchee Valley Medical Center, Wenatchee, Washington, 98801-2028, United States Less <<
NCT00672009	Prostatic Diseases\|Genital Neo... More >>plasms, Male\|Urogenital Neoplasms\|Genital Diseases, Male\|Adenocarcinoma\|Prostatic Neoplasms\|Neoplasms, Glandular and Epithelial\|Carcinoma Less <<	PHASE2	TERMINATED	2025-08-12	Cedars-Sinai Medical Center, L... More >>os Angeles, California, 90048, United States Less <<
NCT00162136	Solid Malignancies	PHASE1	COMPLETED	2025-07-08	University Of Maryland, Baltim... More >>ore, Maryland, 21201, United States\|The Cancer Institute Of New Jersey, New Brunswick, New Jersey, 08901, United States\|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States Less <<
NCT00022477	Colorectal Cancer	PHASE2	COMPLETED	2025-12-04	University of Illinois at Chic... More >>ago, Chicago, Illinois, 60612, United States\|University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States\|Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States\|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, 62526, United States\|Evanston Northwestern Health Care, Evanston, Illinois, 60201, United States\|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States\|LaGrange Memorial Hospital, LaGrange, Illinois, 60525, United States\|Loyola University Medical Center, Maywood, Illinois, 60153, United States\|Lutheran General Cancer Care Center, Park Ridge, Illinois, 60068, United States\|Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, 61602, United States\|Central Illinois Hematology Oncology Center, Springfield, Illinois, 62701, United States\|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46885-5099, United States\|Michiana Hematology/Oncology P.C., South Bend, Indiana, 46601, United States\|Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, 49085, United States\|Albert Einstein Comprehensive Cancer Center, Bronx, New York, 10461, United States Less <<
NCT01027208	Metastatic Breast Cancer	PHASE2	COMPLETED	2025-01-07	Local Institution, Nagoya, Aic... More >>hi, 464-8681, Japan\|Local Institution, Kashiwa-Shi, Chiba, 277-0882, Japan\|Local Institution, Fukuoka-Shi, Fukuoka, Japan\|Local Institution, Matabashi-Shi, Gunma, 371-8511, Japan\|Local Institution, Kagoshima-Shi, Kagoshima, 892-0833, Japan\|Local Institution, Isehara-Shi, Kanagawa, 259-1193, Japan\|Local Institution, Niigata-Shi, Niigata, 951-8566, Japan\|Local Institution, Iruma-Gun, Saitama, 350-0495, Japan\|Local Institution, Utsunomiya, Tochigi, 320-0834, Japan\|Local Institution, Bunkyo-Ku, Tokyo, 113-8677, Japan\|Local Institution, Chuo-Ku, Tokyo, 104-0045, Japan\|Local Institution, Toshima-Ku, Tokyo, 170-8455, Japan\|Local Institution, Saitama, Japan\|Local Institution, Tokyo, Japan Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.97mL 0.39mL 0.20mL	9.87mL 1.97mL 0.99mL	19.74mL 3.95mL 1.97mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed